{"id":7809,"date":"2026-02-24T06:08:29","date_gmt":"2026-02-24T06:08:29","guid":{"rendered":"https:\/\/pandapeptides.com\/research\/bpc-157\/"},"modified":"2026-04-09T14:26:20","modified_gmt":"2026-04-09T21:26:20","slug":"bpc-157","status":"publish","type":"page","link":"https:\/\/pandapeptides.com\/es\/research\/bpc-157\/","title":{"rendered":"BPC-157 \u2014 Published Research"},"content":{"rendered":"
\n

\u2190 Back to BPC-157 product page<\/a><\/p>\n

\n

Biblioteca de investigaci\u00f3n<\/h3>\n

Published research on BPC-157 \u2014 for educational purposes only<\/p>\n

\nBPC-157 and Nitric Oxide System Modulation<\/summary>\n
\n

BPC-157 has been investigated for its interactions with the nitric oxide (NO) system across multiple experimental models. Studies in rats demonstrated that BPC-157 counteracts the effects of both NO synthase inhibitors (L-NAME) and NO synthase substrates (L-arginine) on gastrointestinal motility and vascular tone. This bidirectional modulation suggests the peptide interacts with the NO system at a regulatory rather than direct enzymatic level, potentially involving eNOS and iNOS expression changes.<\/p>\n

Sikiric P et al. “Brain-gut axis and pentadecapeptide BPC 157: Theoretical and practical implications.” Curr Neuropharmacol.<\/em> 2016. PubMed<\/a><\/p>\n<\/div>\n<\/details>\n

\nTendon Fibroblast Growth Hormone Receptor Expression<\/summary>\n
\n

An in vitro study using rat Achilles tendon fibroblasts examined the effects of BPC-157 on growth hormone receptor (GHR) expression. At concentrations from 1 to 100 ng\/mL, the peptide upregulated GHR mRNA expression in a dose-dependent manner. Western blot analysis confirmed increased GHR protein levels. The study also observed increased phosphorylation of JAK2 and STAT5 downstream signaling molecules, suggesting BPC-157 may modulate the GH\/IGF-1 axis at the receptor level in connective tissue cells.<\/p>\n

Chang CH et al. “Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts.” Molecules.<\/em> 2014. PubMed<\/a><\/p>\n<\/div>\n<\/details>\n

\nBPC-157 Gastrointestinal Cytoprotection Research<\/summary>\n
\n

BPC-157 has been studied extensively in gastrointestinal models including ethanol-induced gastric lesions, NSAID-induced intestinal damage, and inflammatory bowel disease models in rats. The peptide demonstrated cytoprotective activity across multiple GI regions . Mechanistic investigations suggest involvement of prostaglandin and dopamine system modulation, as well as effects on VEGF-mediated angiogenesis in damaged mucosal tissue.<\/p>\n

Sikiric P et al. “Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease.” Ann N Y Acad Sci.<\/em> 2006. PubMed<\/a><\/p>\n<\/div>\n<\/details>\n

\nBPC-157 in Musculoskeletal Injury Models<\/summary>\n
\n

A comprehensive review examined BPC-157 research across tendon, ligament, bone, and muscle injury models. Studies in rat Achilles tendon transection models showed accelerated collagen fiber organization. In muscle crush injury models, BPC-157 administration was associated with altered expression of early growth response gene 1 (EGR-1) and its downstream targets including collagen type I and VEGF. The peptide has been studied across these models.<\/p>\n

Vukojevic J et al. “Pentadecapeptide BPC 157 and the central nervous system.” Neural Regen Res.<\/em> 2022. PMC<\/a><\/p>\n<\/div>\n<\/details>\n<\/div>\n

To compare published studies with Panda batch documentation, review Reportes de laboratorio (COAs)<\/a>, Calidad y pruebas<\/a>, la gu\u00eda para evaluar materiales de investigaci\u00f3n<\/a>, o nuestras Preguntas frecuentes<\/a>.<\/p>\n

\n

Disclaimer:<\/strong> All research citations are provided as references to published laboratory literature only. These materials may summarize in vitro and animal-model findings. Products are sold strictly for laboratory research use. No statements on this page are intended as dosing, administration, treatment, or other human-use guidance.<\/p>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

\u2190 Back to BPC-157 product page Research Library Published research on BPC-157 \u2014 for educational purposes only BPC-157 and Nitric Oxide System Modulation BPC-157 has been investigated for its interactions with the nitric oxide (NO) system across multiple experimental models. Studies in rats demonstrated that BPC-157 counteracts the effects of both NO synthase inhibitors (L-NAME) […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":7787,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-7809","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7809","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/comments?post=7809"}],"version-history":[{"count":2,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7809\/revisions"}],"predecessor-version":[{"id":8640,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7809\/revisions\/8640"}],"up":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7787"}],"wp:attachment":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/media?parent=7809"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}